

# Philip Wells

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11026042/publications.pdf>

Version: 2024-02-01

32  
papers

8,716  
citations

430754

18  
h-index

414303

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

7949  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.4	4,060
2	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thrombosis and Haemostasis, 2000, 83, 416-420.	1.8	1,417
3	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine, 1999, 340, 901-907.	13.9	1,052
4	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 349, 631-639.	13.9	728
5	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.4	531
6	An Evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. Annals of Internal Medicine, 2006, 144, 812.	2.0	159
7	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 2008, 112, 4432-4436.	0.6	103
8	Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thrombosis and Haemostasis, 2009, 101, 197-200.	1.8	71
9	The diagnosis and treatment of venous thromboembolism. Hematology American Society of Hematology Education Program, 2013, 2013, 457-463.	0.9	60
10	Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Thrombosis and Haemostasis, 2010, 104, 498-503.	1.8	59
11	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.4	58
12	Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis and Haemostasis, 2010, 104, 760-770.	1.8	51
13	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.4	51
14	Graduated compression stockings to treat acute leg pain associated with proximal DVT. Thrombosis and Haemostasis, 2014, 112, 1137-1141.	1.8	48
15	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	1.8	48
16	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	0.6	45
17	DVT Management and Outcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.4	23
18	The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism. Thrombosis and Haemostasis, 2003, 90, 829-834.	1.8	19

#	ARTICLE	IF	CITATIONS
19	The Diagnosis of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 691-701.	1.5	18
20	Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. <i>Journal of Medical Economics</i> , 2012, 15, 817-828.	1.0	17
21	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 18-24.e1.	0.9	15
22	Cast versus functional brace in the rehabilitation of patients treated for an ankle fracture: protocol for the UK study of ankle injury rehabilitation (AIR) multicentre randomised trial. <i>BMJ Open</i> , 2018, 8, e027242.	0.8	15
23	Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. <i>European Journal of Internal Medicine</i> , 2016, 32, 53-59.	1.0	12
24	Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 341-347.	1.5	12
25	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. <i>American Journal of Medicine</i> , 2017, 130, 482.e1-482.e9.	0.6	9
26	An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears. <i>Trials</i> , 2019, 20, 694.	0.7	9
27	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2406-2414.	1.8	8
28	Applying rigorous eligibility criteria to studies evaluating prognostic utility of serum biomarkers in pulmonary embolism: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 195, 195-208.	0.8	7
29	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	0.7	5
30	Scoring Systems for Diagnosis of Acute Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 479-485.	1.5	3
31	Regarding the necessity of an updated meta-analysis on the prognostic value of serum biomarkers in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2019, 176, 8-10.	0.8	2
32	Life dissatisfaction in Canadians aged 40 and above with cancer and mental health disorders: A cross-sectional study using the Canadian Community Health Survey. <i>Cancer Medicine</i> , 2021, 10, 7601-7609.	1.3	1